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Small molecules that perturb protein homeostasis are used as cancer therapeutics and as antibiotics to treat
bacterial infections. In a recent issue of Cell, Kannan and colleagues describe an intriguing mechanism that
enables ribosome-targeted macrolides to selectively remodel the bacterial proteome. This finding suggests
the exciting possibility of targeting additional proteostasis regulators in a substrate-selective manner.Drugs that target the ribosome are used
globally for treating bacterial infections.
These small molecules, most of which
are microbial natural products or their
derivatives, have also proven invaluable
as tools for unraveling the complex
biochemistry of protein synthesis (Blan-
chard et al., 2010). To date, all clinical
classes of ribosome-targeting antibiotics
bind to the decoding center on the small
subunit, the peptidyl transferase center
(PTC), or the nascent peptide exit tunnel
(NPET). They exert their inhibitory effects
through various mechanisms, including
competition with substrate binding, inhi-
bition of mRNAmovement, and disruption
of ribosome conformational changes.
Binding of antibiotics to these sites is
generally considered to result in global
inhibition of protein synthesis, regardless
of their mechanism of action. A recent
paper in Cell (Kannan et al., 2012)
describes an unexpected mechanism for
the clinically important class of ribo-
some-targeting macrolides in which
a subset of cellular proteins evades mac-
rolide inhibition. Thus, instead of globally
inhibiting protein synthesis, these drugs
selectively remodel the cellular proteome.
This substrate-discriminating ability
depends in part on the precise structure
of the macrolide and may have implica-
tions for the mechanism of bacterial cell
death.
Many ribosome-targeting antibiotics
bind to the PTC and inhibit peptide bond
formation during protein biosynthesis
(Yonath, 2005). By contrast, the erythro-
mycin (ERY) family of clinically important
macrolide antibiotics bind to the prokary-
otic ribosome’s NPET near the L4 and L22
protein loops (Figure 1). Rather than inter-
fering with the peptide bond-forming
step, ERY was thought to sterically block144 Chemistry & Biology 20, February 21, 201the exit tunnel and obstruct nascent chain
elongation, thereby resulting in global
inhibition of translation (Yonath, 2005).
Contradicting this view, Kannan et al.
(2012) report that protein synthesis per-
sists at a low level (5%) in the presence
of saturating concentrations of ERY. Re-
markably, an ERY analog with enhanced
antibiotic potency, telithromycin (TEL),
permits even higher levels of translation
at maximum inhibition (20%). Pulse
labeling with 35S-Met, coupled with
two-dimensional gel electrophoresis and
mass spectrometry, revealed a small
subset of proteins that are resistant to
ERY and TEL.
To elucidate the mechanism of this
effect, the authors asked if specific amino
acid sequences near the N terminus
of the nascent polypeptide, which first
encounter the bound macrolide in the
ribosome exit tunnel, can promote eva-
sion of ERY-mediated translation arrest.
Experiments with H-NS, a macrolide-
resistant protein identified by mass spec-
trometry, established that its first 12
amino acids are sufficient to confer resis-
tance when transferred to the N terminus
of an otherwise sensitive protein. How
could this be? Whereas previous crys-
tallographic studies had suggested that
macrolide binding dramatically con-
stricts the exit tunnel and thereby pre-
vents nascent chain elongation (Schlu¨n-
zen et al., 2001), a more recent study
proposed that occlusion is incomplete
and might permit wriggling of some poly-
peptides past the bound macrolide
(Tu et al., 2005). An elegant experiment,
in which an ERY-dependent transla-
tional stall sequence was fused to the
C terminus of the ERY-resistant H-NS
protein, suggested that the nascent poly-
peptide is able to thread through the3 ª2013 Elsevier Ltd All rights reservedexit tunnel while the macrolide remains
bound. Given the lack of sequence
homology between the macrolide-resis-
tant proteins identified in this study, an
important question for the future con-
cerns the structural or physicochemical
requirements of the nascent chain for
bypassing the partially occluded exit
tunnel.
For nascent polypeptides that initially
manage to slither past the bound macro-
lide, stalling can still occur at longer
chain lengths due to specific internal
sequences that presumably clash with
the macrolide (indeed, the probability of
stalling appears to increase with polypep-
tide length). In this case, translation arrest
leads to the generation of truncated
proteins. The authors suggest that partial
translation inhibition by macrolide antibi-
otics such as TEL may result in enhanced
cytotoxicity due to the accumulation of
truncated proteins with altered functions.
However, this provocative model remains
to be tested.
This intriguing twist in themechanism of
macrolide antibiotics is reminiscent of the
cotransins, a family of cyclic peptides that
includes the fungal natural product CAM-
741 and its synthetic variants. Like ribo-
some-targeting macrolides, cotransins
target a universally conserved protein
biogenesis machine: in this case, the
Sec61 translocation channel required for
the functional expression of most secre-
tory and integral membrane proteins
(Besemer et al., 2005; Garrison et al.,
2005). Cotransins potently inhibit Sec61-
mediated cotranslational translocation of
nascent secretory and membrane pro-
teins into the endoplasmic reticulum (ER)
of mammalian cells. Moreover, they do
so in a substrate-discriminatory manner.
They bind directly to the a subunit of the
Figure 1. Substrate-Selective Modulators of Protein Biogenesis
Left: ERY-class macrolides bind to the NPET between the 50S (blue) and 30S
(green) subunits of the bacterial ribosome. Depending on the sequence of
the nascent polypeptide, this can result in (1) drop-off of peptidyl-tRNA during
early rounds of translation, (2) N-terminal translation arrest, and (3) N-terminal
bypass, followed by late translation arrest or synthesis of the full-length
polypeptide.
Right: Cotransins (e.g., CT08; Maifeld et al., 2011) bind the Sec61a subunit
of the mammalian translocation channel. Depending on the N-terminal signal
sequence of the nascent secretory ormembrane protein, cotransins can inhibit
cotranslational translocation or membrane integration. The encoding mRNA
is drawn in purple and the emerging polypeptide chain in green. The ER
membrane is indicated as black lines.
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et al., 2007), which recog-
nizes the N-terminal signal
sequences (or transmem-
brane domains) of substrate
proteins. The productive in-
teraction between Sec61
and a hydrophobic signal is
required for channel gating
and translocation of nascent
polypeptides into the ER
lumen in addition to medi-
ating integration of trans-
membrane segments into the
lipid bilayer (Shao andHegde,
2011). By analogy to themac-
rolide antibiotics, cotransin
sensitivity of any given secre-
tory protein is determined by
specific sequences near the
N terminus: in this case, the
signal sequence (Besemer
et al., 2005; Garrison et al.,
2005). However, the precise
sequence requirements for
cotransin sensitivity remain
unknown. Finally, cotransin
structural variants with dis-
tinct substrate selectivities
have been described (Harant
et al., 2007; Maifeld et al.,2011). Similar to theproposed explanation
for the differential effects of macrolide
variants on protein translation (Kannan
et al., 2012), it is likely that cotransin vari-
ants exert distinct effects on the kinetic
discrimination of translocating polypep-
tides by the Sec61 channel.
An exciting concept emerging from
these studies is the possibility of identi-
fying small, drug-like molecules that
modulate core regulators of protein
homeostasis, not by completely shutting
them down, but by enhancing their
innate ability to kinetically discriminate
between different protein substrates. To
fully harness the substrate-discriminatory
potential of such compounds, it will be
necessary to obtain a detailed under-standing of (1) their binding modes
(structure and kinetics), (2) the binding
modes of sensitive and resistant sub-
strates, and (3) the structure/sequence/
physicochemical requirements of the
polypeptide substrate for compound
sensitivity. In addition to their potential
therapeutic utility, these compounds
can help us understand the physical prin-
ciples that enable complex cellular
machines to recognize and discriminate
among diverse protein (and possibly,
nucleic acid) substrates. Finally, the co-
transin and ERY examples inspire the
search for substrate-selective modula-
tors of cellular machines that control
other aspects of protein and nucleic
acid homeostasis, including chaperone/Chemistry & Biology 20, February 21, 2013 ª2013 Elseco-chaperone complexes,
the proteasome, the spliceo-
some, and nuclear export
factors, all of which have
been targeted by small
molecules.
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